Myocardial infarction within the past 6 months
Patients must not have a myocardial infarction within 6 months prior to registration
History of myocardial infarction within 6 months.
Acute myocardial infarction </=6 months prior to enrollment
Myocardial infarction within 6 months prior to study entry,
Myocardial infarction within the last 6 months
Acute myocardial infarction ?6 months prior to Day 1
Myocardial infarction within the previous 6 months before planned first dose of study drug
Myocardial infarction within 6 months of study dose
Subjects with myocardial infarction (heart attack) within 1 year
No uncontrolled arrhythmia; no myocardial infarction in the last 6 months
Myocardial infarction within 6 months prior to initiation of screening
Other serious intercurrent chronic or acute illness, including myocardial infarction or cerebrovascular event within 6 months
Any history of myocardial infarction in the past 12 months
Myocardial infarction and/or new ST elevation
Myocardial infarction,
Myocardial infarction within 6 months prior to screening, or pericardial effusion,
Have a recent history of myocardial infarction (within the past 2 months)
History of myocardial infarction within the last 6 months.
Myocardial infarction in the previous 12 weeks (from the start of treatment)
History of myocardial infarction within 6 months of the randomization
Patients within 6 months of myocardial infarction (MI) and stroke will be excluded
Myocardial infarction (MI) within 6 months of Screening Visit.
Myocardial infarction within the 6 months prior to study drug administration
History of a recent myocardial infarction (within one year), a past myocardial infarction (more than one year ago) along with current coronary symptoms requiring medications
Has history of myocardial infarction within the past 6 months.
Myocardial infarction within 3 months of registration.
Myocardial infarction within 6 months of starting study drug
Myocardial infarction within 6 months
History of myocardial infarction within 6 months prior to registration
Patients with history of myocardial infarction within 6 months
No stroke, myocardial infarction, or major surgery within 3 months of starting on therapy
Myocardial infarction within 6 months of study entry
No evidence of a history of a stroke or myocardial infarction within the last 6 months prior to study enrollment
No uncontrolled arrhythmia; no myocardial infarction in the last 6 months
Active ischemic heart disease or history of myocardial infarction within six months.
Myocardial infarction within 6 months of study entry
Myocardial infarction less than 6 months before study enrollment
Myocardial infarction or cardiac surgery within 6 months prior to enrollment
myocardial infarction in the previous six months
Myocardial infarction (MI) within 3 months. • Presence of active, uncontrolled infection. • Known central nervous system illness (e.g., Alzheimer's disease).
Myocardial infarction
History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within 6 months
Subjects that have had a myocardial infarction within the last 6 months
Patients with a history of myocardial infarction that is < 3 months prior to registration
Patients with a history of myocardial infarction that is < 3 months prior to registration
Transmural myocardial infarction within the last 6 months
History of myocardial infarction within 6 months
Myocardial infarction < 6 months prior to screening
Patients with a history of myocardial infarction or stroke within the last 6 months
Documented myocardial infarction within six months of enrollment.
Myocardial infarction (MI) within 6 months prior to the first dose of study drug;
Myocardial infarction (MI) within past 6 months before randomization
History of myocardial infarction within 6 months of study entry.
Myocardial infarction within 6 months prior to study entry
Active ischemic heart disease or history of myocardial infarction within six months.
Patients with documented myocardial infarction within six months of protocol entry
Myocardial infarction (MI) within the last 3 months
Recent (within twelve months) myocardial infarction.
Evidence of a history of a stroke or myocardial infarction within the last 6 months prior to study enrollment
Patients with a history of myocardial infarction that is < 3 months prior to registration
Myocardial infarction within 3 months of study initiation
History of myocardial infarction within 6 months of enrollment.
Transmural myocardial infarction within 3 months prior to step 1 registration
History of myocardial infarction
Acute myocardial infarction =< 12 months prior to starting drug
Subjects with a history of myocardial infarction within the last 6 months of screening.
Patients with a history of myocardial infarction within the 6 months prior to screening
Myocardial infarction
Myocardial infarction
Patients who have had a myocardial infarction within 6 months (24 weeks) prior to registration are not eligible
Transmural myocardial infarction within the last 6 months
myocardial infarction within 6 months prior to randomization;
No myocardial infarction < 6 months
Myocardial infarction
History of myocardial infarction within 6 months.
Myocardial infarction
Transmural myocardial infarction within the last 6 months
Myocardial infarction within the last 3 months
Transmural myocardial infarction within the last 6 months prior to registration
Patients who have had a myocardial infarction, intracranial bleed, or stroke within the past 6 months are not eligible
Subjects with active cardiovascular disease not medically controlled or those who have had myocardial infarction in the past 6 months..
Myocardial infarction within 6 months before the Day 1 visit.
History of myocardial infarction within 6 months prior to screening
Myocardial infarction within 6 months before C1D1.
Documented myocardial infarction <6 months from study entry
Acute myocardial infarction
Myocardial infarction (MI) within 6 months prior to the first dose of brigatinib
Subjects with a history of myocardial infarction within the last 6 months.
Myocardial infarction
Myocardial infarction within 6 months of registration
Patients within three months of a myocardial infarction
Myocardial infarction in the previous 12 weeks (from the start of treatment)
Subjects with a history of myocardial infarction within the last 6 months of screening.
Myocardial infarction in the previous 12 weeks (from the start of treatment)
Patients with a history of myocardial infarction that is < 3 months prior to registration
History of a myocardial infarction within 6 months
Myocardial infarction within the past 6 months before the first dose of study drug
History of myocardial infarction within 12 months prior to day 1 or clinically significant coronary disease
History of myocardial infarction within 6 months of enrollment
Myocardial infarction within 12 months prior to starting study
Myocardial infarction within four months prior to enrollment
Myocardial infarction within 6 months of treatment
History of myocardial infarction within 6 months prior to day 1
Acute myocardial infarction ?6 months prior to study participation
Myocardial infarction within 3 months prior to starting treatment
Patients with a history of myocardial infarction that is < 3 months prior to registration
Myocardial infarction in the previous 12 weeks (from the start of treatment)
History of myocardial infarction within 6 months
Past history of myocardial infarction in the prior 12 months
Myocardial infarction ? 6 months prior to enrolment.
History of myocardial infarction within 6 months prior to the first dose of study-drug treatment in Cycle 1
Myocardial infarction <6 months from study entry
History of myocardial infarction within the last 6 months
Myocardial infarction within 6 months prior to screening;
Myocardial infarction (MI) within 6 months prior to first study drug administration
Acute myocardial infarction ? 3 months prior to starting study drug
Myocardial infarction (MI) within 6 months prior to first study drug administration
Myocardial infarction within 6 months of Screening visit;
History of myocardial infarction within 6 months of Cycle 1, Day 1
History of myocardial infarction within 6 months prior to screening
Subject has had an acute myocardial infarction (AMI)
Cardiomyopathy or a myocardial infarction within the past 8 months.
Myocardial infarction (MI) within the prior 3 months
History of myocardial infarction within 6 months prior to first dose of study drug
Any history of myocardial infarction in the past 12 months
A myocardial infarction within 6 months prior to study entry;
Patients with documented myocardial infarction within six months of protocol entry
Myocardial infarction 6 months prior to screening
Acute myocardial infarction within 6 months before starting study drug.
Transmural myocardial infarction within the last 6 months prior to registration
Active myocardial ischemia (acute ST elevation or non ST elevation myocardial infarction [MI])
Patients with a history of myocardial infarction or ischemic heart disease within the past six months
Myocardial Infarction (MI) within 3 months
History of myocardial infarction or ischemic heart disease within the past six months
Patients with a history of myocardial infarction or ischemic heart disease within the past six months
Recent myocardial infarction
No clinical history of acute myocardial infarction within six months of registration
myocardial infarction (within the last 3 months)
Myocardial infarction (MI) in the last 6 months
Myocardial infarction
Recent myocardial infarction
History of myocardial infarction within 6 months of the enrollment
Acute myocardial infarction within 28 days
Has history of myocardial infarction within the past 6 months
Myocardial infarction within 3 months prior to C1D1.
History of prior myocardial infarction or arrhythmia
Acute myocardial infarction within 6 months before starting study drug.
Myocardial infarction within the last 6 months
Myocardial infarction within the last 6 months
